Related Experiment Video
Updated: May 22, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Research of SOCS1 silent DC vaccine on laryngocarcinoma therapy]
Yang Yuan1, Xuefeng Wang, Yang Zhang
1Department of Otolaryngology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, China.
Objective:
Investigate the specific antitumor mechanism of SOCS1 silent DC vaccine and discuss the prospect of RNAi in the gene therapy for laryngocarcinoma in order to provide novel ideas of DCs clinical applications.
Method:
Dendritic cells derived from peripheral blood monocytes were cultured in vitro in the presence of GM-CSF, IL-4 and TNF-alpha. The morphological feature of DC was observed with inverted microscope. RNAi vector were transfected into DC. The expression of SOCS1 protein was detected with Western blot. The effective target sequences of siRNA against SOCS1 were screened out. The surface markers of mature DC, including CD83, CD86 and HLA-DR, were detected with flow cytometry. The concentration of IFN-gamma in the supernatant was assayed by ELISA. The proliferative ability of T cell stimulated by DC and the specific killing activity of cytotoxic T lymphocyte (CTL) induced by DC were evaluated by MTT assay.
Result:
Dendritic cells were obtained successfully. The RNAi vector was proved to be right by sequencing. The expression of SOCS1 decreased significantly under the influence of the 5th interference sequence. SOCS1 silent dendritic cells which were loaded with Hep-2 antigen had high expressions of CD83 (85.61 +/- 0.96)%, CD86 (96.86 +/- 1.20)% and HLA-DR (98.02 +/- 0.94)%. It could also stimulate the proliferation of T cells effectively as well as could increase the production of IFN-gamma, eventually enhanced the specific killing effect of CTL. The killing activity was more higher than that in control group when the effect cells and target cells were mixed up at the ratio of 50:1 (P < 0.01).
Conclusion:
SOCS1 silent DC vaccines which were loaded with Hep-2 antigen could induce effective and specific anti-laryngocarcinoma immune responses.
Insights
This study demonstrates that a dendritic cell (DC) vaccine with silenced SOCS1 (suppressor of cytokine signaling 1) effectively targets laryngocarcinoma. This approach shows promise for RNA interference (RNAi) gene therapy in treating this cancer.
Area of Science:
- Immunotherapy
- Gene Therapy
- Cancer Research
Background:
- Dendritic cells (DCs) are crucial for initiating immune responses.
- Laryngocarcinoma presents a significant challenge in cancer treatment.
- RNA interference (RNAi) offers a targeted approach for gene silencing.
Purpose of the Study:
- To investigate the antitumor mechanism of a SOCS1-silenced DC vaccine.
- To evaluate the potential of RNAi in laryngocarcinoma gene therapy.
- To explore novel clinical applications for DCs.
Main Methods:
- DCs were cultured and transfected with RNAi vectors targeting SOCS1.
- SOCS1 expression was confirmed via Western blot.
- DC maturation markers (CD83, CD86, HLA-DR), T cell proliferation, and CTL activity were assessed.
Main Results:
- SOCS1 silencing was successfully achieved using RNAi.
- SOCS1-silenced DCs exhibited mature surface marker expression.
- These DCs effectively stimulated T cell proliferation, increased IFN-gamma production, and enhanced CTL-mediated killing of laryngocarcinoma cells.
Conclusions:
- SOCS1-silenced DC vaccines loaded with tumor antigen induce specific anti-laryngocarcinoma immune responses.
- This strategy holds potential for laryngocarcinoma gene therapy.
- Further research into DC-based vaccines is warranted for clinical applications.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers